English
全部
图片
灵感
创建
集合
视频
地图
资讯
购物
更多
航班
旅游
酒店
笔记本
自动播放所有 GIF
在这里更改自动播放及其他图像设置
自动播放所有 GIF
拨动开关以打开
自动播放 GIF
图片尺寸
全部
小
中
大
特大
至少... *
自定义宽度
x
自定义高度
像素
请为宽度和高度输入一个数字
颜色
全部
彩色
黑白
类型
全部
照片
插图
素描
动画 GIF
透明
版式
全部
方形
横版
竖版
人物
全部
脸部特写
半身像
日期
全部
过去 24 小时
过去一周
过去一个月
去年
授权
全部
所有创作共用
公共领域
免费分享和使用
在商业上免费分享和使用
免费修改、分享和使用
在商业上免费修改、分享和使用
详细了解
重置
安全搜索:
中等
严格
中等(默认)
关闭
筛选器
2400×1139
www.urotoday.com
#AUA14 - Poster: Further characterization of the effects of prior or no ...
2400×1511
UroToday
EAU 2014 - Poster: Consistent improvements in urinary urgency following ...
2400×1044
www.urotoday.com
GU Cancers Symposium 2014 - Response to androgen signaling-directed ...
1200×669
www.urotoday.com
ESMO 2022: Outcomes of Relapsed Clinical Stage I Versus De Novo ...
1200×588
www.urotoday.com
ESMO 2023: MEDI5752 (Volrustomig), a Novel PD-1/CTLA-4 Bispecific ...
1200×610
www.urotoday.com
ESMO 2023: EV-302/KEYNOTE-A39: Enfortumab Vedotin in Combination with ...
1200×610
www.urotoday.com
ESMO 2023: EV-302/KEYNOTE-A39: Enfortumab Vedotin in Combination with ...
1200×621
www.urotoday.com
ESMO 2023: EV-302/KEYNOTE-A39: Enfortumab Vedotin in Combination with ...
1200×610
www.urotoday.com
ESMO 2023: EV-302/KEYNOTE-A39: Enfortumab Vedotin in Combination with ...
1200×617
www.urotoday.com
ESMO 2023: EV-302/KEYNOTE-A39: Enfortumab Vedotin in Combination with ...
1200×569
www.urotoday.com
ESMO 2023: EV-302/KEYNOTE-A39: Enfortumab Vedotin in Combination with ...
1200×632
www.urotoday.com
ESMO 2023: EV-302/KEYNOTE-A39: Enfortumab Vedotin in Combination with ...
1200×624
www.urotoday.com
ESMO 2023: EV-302/KEYNOTE-A39: Enfortumab Vedotin in Combination with ...
1200×572
www.urotoday.com
ESMO 2023: EV-302/KEYNOTE-A39: Enfortumab Vedotin in Combination with ...
1200×581
www.urotoday.com
ESMO 2023: EV-302/KEYNOTE-A39: Enfortumab Vedotin in Combination with ...
1124×638
www.urotoday.com
ESMO 2022: Avelumab First-Line Maintenance for Advanced Urothelial ...
1200×1658
www.urotoday.com
ASCO 2024: Zanzalintinib (…
996×726
www.urotoday.com
ASCO 2023: Pembrolizumab + Axitinib Versus Sunitinib as First-Line ...
2412×1104
UroToday
PI-RADS 3 Lesions: Does the Association of the Lesion Volume with the ...
1200×574
www.urotoday.com
ESMO 2024: Final Analysis of the Phase 3 LITESPARK-005 Study of ...
1200×581
www.urotoday.com
ESMO 2024: Final Analysis of the Phase 3 LITESPARK-005 Study of ...
1200×579
www.urotoday.com
ESMO 2024: Final Analysis of the Phase 3 LITESPARK-005 Study of ...
1200×573
www.urotoday.com
ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following ...
1200×590
www.urotoday.com
ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following ...
1200×679
www.urotoday.com
ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following ...
1200×705
www.urotoday.com
ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following ...
1200×628
www.urotoday.com
ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following ...
1200×632
www.urotoday.com
ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following ...
1081×777
www.urotoday.com
ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-…
1200×630
www.urotoday.com
ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following ...
1200×660
www.urotoday.com
ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following ...
1200×618
www.urotoday.com
ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following ...
2400×1750
www.urotoday.com
SES AUA 2014 - Poster and Abstract: Prospective evaluation of 24-hour ...
1028×666
www.urotoday.com
ESMO 2022: Phase 2 Clinical Study Evaluating the Efficacy and Safety of ...
1024×672
www.urotoday.com
ESMO 2022: Phase 2 Clinical Study Evaluating the Efficacy and Safety of ...
某些结果已被隐藏,因为你可能无法访问这些结果。
显示无法访问的结果
报告不当内容
请选择下列任一选项。
无关
低俗内容
成人
儿童性侵犯
反馈